Medicare Enrolled

Dr. Marianne Santioni, DO

Rheumatology · Old Forge, PA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
821 S MAIN ST, Old Forge, PA 18518
5704570562
In practice since 2006 (20 years)
NPI: 1205868668 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Santioni from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Santioni? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Santioni

Dr. Marianne Santioni is a rheumatology specialist in Old Forge, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Santioni performed 20,570 Medicare services across 989 unique beneficiaries.

Between the years covered by Open Payments, Dr. Santioni received a total of $24,164 from 48 pharmaceutical and/or device companies across 1534 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Santioni is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 30% volume in PA $24,164 industry payments

Medicare Practice Summary

Medicare Utilization ↗
20,570
Medicare services
Top 30% in PA for rheumatology
989
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,028 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
11,682 $10 $35
Denosumab injection (Prolia/Xgeva) 6,000 $18 $28
Joint lubricant injection (Durolane)
An injection of hyaluronan or its derivative, specifically Durolane, administered directly into a joint space.
1,141 $5 $20
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
739 $85 $197
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
215 $99 $226
Injection, methylprednisolone acetate, 40 mg 197 $6 $20
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
181 $63 $140
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
128 $49 $109
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
128 $11 $70
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
63 $9 $60
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
43 $121 $297
Joint fluid aspiration or injection, small joint
Removal of fluid from a small joint or injection of medication into a small joint.
29 $30 $85
Joint fluid aspiration or injection, medium joint
Removal of fluid from a medium-sized joint or injection of medication into the joint space.
24 $33 $95
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
57.8% high complexity
37.5% medium
4.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$24,164
Total received (2018-2024)
Avg $3,452/year across 7 years
Top 16% in PA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
48
Companies
1,534
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,164 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,374
2023
$3,057
2022
$2,951
2021
$3,486
2020
$2,747
2019
$5,495
2018
$4,054

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$583
Amgen Inc.
$411
UCB, Inc.
$354
Novartis Pharmaceuticals Corporation
$276
Janssen Biotech, Inc.
$160
PFIZER INC.
$134
Organon Llc
$104
GlaxoSmithKline, LLC.
$84
AstraZeneca Pharmaceuticals LP
$83
Alexion Pharmaceuticals, Inc.
$55
E.R. Squibb & Sons, L.L.C.
$36
Mallinckrodt Hospital Products Inc.
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$18
ANI Pharmaceuticals, Inc.
$15
Radius Health, Inc.
$15
GENZYME CORPORATION
$15
Top 3 companies account for 56.8% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$4,492
UCB, Inc.
$2,574
Janssen Biotech, Inc.
$2,431
PFIZER INC.
$1,965
Novartis Pharmaceuticals Corporation
$1,709
AbbVie Inc.
$1,472
ABBVIE INC.
$1,132
Genentech USA, Inc.
$1,034
AbbVie, Inc.
$1,022
Mallinckrodt Hospital Products Inc.
$630
Amarin Pharma Inc.
$598
E.R. Squibb & Sons, L.L.C.
$492
GlaxoSmithKline, LLC.
$483
Flexion Therapeutics, Inc.
$446
GENZYME CORPORATION
$364
Lilly USA, LLC
$361
Boehringer Ingelheim Pharmaceuticals, Inc.
$283
Mallinckrodt Enterprises LLC
$277
AstraZeneca Pharmaceuticals LP
$244
Alexion Pharmaceuticals, Inc.
$235
Radius Health, Inc.
$213
SANOFI-AVENTIS U.S. LLC
$198
Janssen Scientific Affairs, LLC
$195
Aurinia Pharma U.S., Inc.
$171
Mallinckrodt LLC
$170
Organon Llc
$104
Organon LLC
$99
Celgene Corporation
$97
ANI Pharmaceuticals, Inc.
$70
Exeltis, USA Inc.
$67
Bioventus LLC
$64
Collegium Pharmaceutical, Inc.
$63
Horizon Therapeutics plc
$46
Horizon Pharma plc
$44
Fresenius Kabi USA, LLC
$39
Takeda Pharmaceuticals U.S.A., Inc.
$38
Sobi, Inc
$33
BIODELIVERY SCIENCES INTERNATIONAL, INC.
$33
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$31
Kaleo, Inc.
$24
Kiniksa Pharmaceuticals, Ltd.
$21
IBSA Pharma Inc.
$16
Purdue Pharma L.P.
$15
Daiichi Sankyo Inc.
$14
ASSERTIO THERAPEUTICS, Inc.
$14
Pacira Therapeutics, Inc.
$14
Kowa Pharmaceuticals America, Inc.
$13
BioDelivery Sciences International, Inc.
$13
Top 3 companies account for 39.3% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BELBUCA · BENLYSTA · Belbuca · Bimzelx · COLOGUARD DNA CAPTURE REAGENTS · COSENTYX · CYLTEZO · Cimzia · Durolane · EVENITY · EVUSHELD · EVZIO · Enbrel · Evzio · GELSYN 3 · HADLIMA · HUMIRA · Humira · IDACIO · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LIVALO · LUPKYNIS · LYRICA · Licart · Morphabond ER · OFEV · ORENCIA · Otezla · PREVNAR - 13 · PURIFIED CORTROPHIN GEL · Prolia · RELISTOR ORAL · REMICADE · RENFLEXIS · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYMPROIC · SYNVISC-ONE · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · Uloric · Vascepa · XELJANZ · XTAMPZA · Zilretta · Zipsor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Old Forge?
Compare rheumatologists in the Old Forge area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
13
Per 100K population
6.0
County median income
$64,691
Nearest hospital
GEISINGER BEHAVIORAL HEALTH CENTER NORTHEAST
3.2 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Santioni is a mixed practice specialist, with above-average Medicare volume (top 30% in PA), with low-engagement industry engagement in the top 16% of PA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Santioni experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Santioni performed 11,682 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Santioni receive payments from pharmaceutical companies?
Yes. Dr. Santioni received a total of $24,164 from 48 companies across 1,534 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Santioni's costs compare to other rheumatologists in Old Forge?
Dr. Santioni's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Santioni) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →